Abstract: The present disclosure provides a new procedure for preparing a key intermediate for active pharmaceutical ingredients useful in the treatment of diseases related to the central nervous system.
Type:
Application
Filed:
July 12, 2022
Publication date:
February 23, 2023
Applicant:
DIPHARMA FRANCIS S.R.L.
Inventors:
Francesca Della Penna, Valeria Nori, Fabio Pesciaioli, Armando Carlone
Abstract: The invention relates to a process for preparing a compound of formula (I) in particular obeticholic acid and intermediates suitable for its synthesis.
Abstract: The invention relates to a process for preparing a compound of formula (I) in particular obeticholic acid and intermediates suitable for its synthesis.
Abstract: The present invention relates to a process for the preparation of selegiline base, an irreversible and selective inhibitor of the MAO-B enzymes and which is used in the treatment of Parkinson's Disease.
Type:
Grant
Filed:
January 24, 2018
Date of Patent:
March 24, 2020
Assignee:
Dipharma Francis S.r.L.
Inventors:
Alessandro Restelli, Gabriele Razzetti, Alessandro de Marco
Abstract: The present invention relates to a process for the preparation of an inhibitor of phosphodiesterase 4, in particular of phosphodiesterase 4B (PDE4B), and intermediates useful for its preparation.
Abstract: The present invention relates to a process for the preparation of an inhibitor of phosphodiesterase 4, in particular of phosphodiesterase 4B (PDE4B), and intermediates useful for its preparation.
Abstract: The present invention relates to a process for the preparation of anhydrous crystalline 2-(R)-[(3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl]-1H-benzimidazole (dexlansoprazole).
Abstract: The invention relates to a process for preparing a compound of formula (I) in particular obeticholic acid and intermediates suitable for its synthesis.
Abstract: The present invention relates to a process for the preparation of selegiline base, an irreversible and selective inhibitor of the MAO-B enzymes and which is used in the treatment of Parkinson's Disease.
Type:
Application
Filed:
January 24, 2018
Publication date:
July 26, 2018
Applicant:
Dipharma Francis S.r.l..
Inventors:
Alessandro Restelli, Gabriele Razzetti, Alessandro de Marco
Abstract: The present invention relates to a process for the preparation of pirfenidone, an immunosuppressive drug developed for the treatment of idiopathic pulmonary fibrosis.
Abstract: The present invention relates to a new process for the isolation and purification of 6-aminocaproic acid, which is a known inhibitor of enzymes responsible for fibrinolysis and is used in the treatment of coagulopathies and severe post-operative bleedings.
Abstract: Substantially stable to degradation Fesoterodine fumarate, a process for its preparation and a process for the synthesis of specific degradation impurities of Fesoterodine fumarate are disclosed.
Type:
Grant
Filed:
June 23, 2015
Date of Patent:
September 5, 2017
Assignee:
Dipharma Francis S.r.l.
Inventors:
Pietro Allegrini, Emanuele Attolino, Renzo Graziosi
Abstract: The present invention relates to novel crystalline forms of vortioxetine hydrobromide, in particular three crystalline forms, a process for their preparation, a pharmaceutical composition containing said novel crystalline forms, and a process for the purification of vortioxetine or a salt thereof, comprising the formation of one or more of the novel crystalline forms of vortioxetine hydrobromide described herein.
Type:
Grant
Filed:
July 6, 2015
Date of Patent:
June 27, 2017
Assignee:
Dipharma Francis S.r.l.
Inventors:
Stefano Luca Giaffreda, Marco Curzi, Elena Dichiarante, Pietro Allegrini, Renzo Graziosi, Chiara Vladiskovic
Abstract: The present invention relates to azidoalkylamine salts of formula (I) with organic acids, a process for their preparation, and their use as intermediates in the preparation of active pharmaceutical ingredients or polymers, or as spacers useful in organis synthesis.
Type:
Application
Filed:
May 26, 2015
Publication date:
April 13, 2017
Applicant:
DIPHARMA FRANCIS S.R.L.
Inventors:
Pietro ALLEGRINI, Gabriele RAZZETTI, Dario PASTORELLO
Abstract: The present invention relates to a new process for the isolation and purification of 6-aminocaproic acid, which is a known inhibitor of enzymes responsible for fibrinolysis and is used in the treatment of coagulopathies and severe post-operative bleedings.
Abstract: The present invention relates to a process for the preparation of 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine of formula (I), also known as vortioxetine, salts thereof, and intermediates useful for its synthesis.
Type:
Grant
Filed:
November 19, 2015
Date of Patent:
January 24, 2017
Assignee:
Dipharma Francis S.r.l.
Inventors:
Luca Giannotti, Renzo Graziosi, Emanuele Attolino, Pietro Allegrini